Pancreatic Cancer Breakthrough: Scientists in Spain Achieve Pancreatic Tumour Regression in Mice Using Triple Therapy

A Groundbreaking Achievement from Spain's CNIO Researchers

In a remarkable advancement for oncology research, scientists at Spain's Centro Nacional de Investigaciones Oncológicas (CNIO, Spanish National Cancer Research Centre) have demonstrated complete pancreatic tumour regression in advanced mouse models using a novel triple therapy. Led by renowned researcher Mariano Barbacid, the team published their findings in the Proceedings of the National Academy of Sciences (PNAS) in December 2025, marking a potential paradigm shift in tackling one of Europe's deadliest cancers.

The study targeted pancreatic ductal adenocarcinoma (PDAC), the predominant form of pancreatic cancer, which accounts for over 90% of cases. In Spain alone, more than 10,300 new diagnoses occur annually, with a grim five-year survival rate below 10%. Across Europe, the incidence remains high at approximately 2.31 per 100,000 population, underscoring the urgent need for innovative treatments.

This preclinical success, achieved without tumour resistance or significant toxicity, highlights the power of multi-targeted strategies in preclinical models. While human applications remain distant, the results inspire optimism for future clinical developments.

Understanding Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic ductal adenocarcinoma originates in the ducts of the pancreas, the organ responsible for producing digestive enzymes and hormones like insulin. Early symptoms—such as abdominal pain, jaundice, and unexplained weight loss—are often vague, leading to diagnosis at advanced stages when the cancer has metastasized.

Europe faces a disproportionate burden: mortality rates have risen steadily, with Spain reporting 7,973 pancreatic cancer deaths in 2022, up from 6,039 in 2013. Projections for the European Union indicate around 1.23 million total cancer deaths in 2026, with pancreatic cancer contributing significantly due to aging populations and lifestyle factors like obesity and smoking.

Traditional chemotherapy offers limited benefits, with median survival hovering at 6-12 months post-diagnosis. Recent approvals of KRAS inhibitors in 2021 represented progress, but rapid resistance development—within months—has curtailed their impact.

The Central Role of KRAS Mutations

KRAS (Kirsten rat sarcoma viral oncogene homolog) mutations drive nearly 90-95% of PDAC cases. This oncogene activates downstream signaling pathways promoting uncontrolled cell proliferation, survival, and metastasis. Once mutated, KRAS locks into an active state, fueling tumour growth.

Targeting KRAS has been notoriously difficult—deemed "undruggable" for decades—until recent breakthroughs. Single-agent inhibitors like those approved in 2021 initially shrink tumours but fail as cancer cells adapt via bypass pathways. The CNIO study addresses this by simultaneously blocking three critical nodes: downstream (RAF1), upstream (EGFR), and orthogonal (STAT3) branches of the KRAS pathway.

This multi-pronged approach prevents escape mechanisms, a strategy gaining traction in European research hubs from Madrid to Salamanca.

Dissecting the Triple Therapy Components

The CNIO triple therapy combines three agents, each precision-engineered to disrupt KRAS signaling:

• RMC-6236 (also known as daraxonrasib): A pan-RAS inhibitor that directly binds and inactivates mutant KRAS, halting its oncogenic signaling at the source. Developed by Revolution Medicines, it's in early clinical trials for various cancers.
• Afatinib: An irreversible tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR) family, including EGFR and HER2. Already FDA and EMA-approved for non-small cell lung cancer, it blocks upstream activation of KRAS.
• SD36: A selective degrader of STAT3 (signal transducer and activator of transcription 3), a parallel pathway that supports tumour survival and immune evasion. This novel agent degrades the protein rather than merely inhibiting it.

Administered together, these drugs synergize to dismantle the tumour's survival network step-by-step: first inhibiting KRAS, then sealing upstream and parallel reinforcements.

Experimental Design and Mouse Model Insights

The researchers employed sophisticated orthotopic mouse models, implanting human-like PDAC tumours directly into the pancreas to mimic natural disease progression. These included KRAS/TP53-mutant models, genetically engineered mice (GEMMs), and patient-derived xenografts (PDX) for translational relevance.

Treatment began at advanced stages, reflecting real-world late diagnoses. Step-by-step monitoring via imaging and histology revealed rapid tumour shrinkage, followed by complete eradication in 16 of 18 mice within weeks. Critically, no relapses occurred over 200+ days post-treatment.

Toxicity was minimal, with no weight loss or organ damage, unlike aggressive chemotherapies. Genetic ablation experiments validated the mechanism, confirming triple blockade as essential.

Photo by Markus Winkler on Unsplash

Overcoming the Resistance Barrier

Tumour resistance plagues single KRAS inhibitors, as cells reroute signals through EGFR feedback or STAT3-mediated survival. The triple therapy preempts this by comprehensive pathway shutdown, achieving durable responses unprecedented in PDAC models.

This mirrors successes in other cancers, like BRAF-mutant melanomas with dual blockade. For PDAC, it offers a blueprint: combination therapies tailored to molecular vulnerabilities.

European collaborators, including Universidad de Salamanca and Universidad Autónoma de Madrid, contributed expertise in mouse engineering and pathology, exemplifying interdisciplinary higher education synergies. Explore research jobs driving such innovations across Europe.

Implications for European Higher Education and Research

CNIO's work, funded by ERC grants, CIBERONC, and EU Next Generation funds, underscores Spain's rising oncology prowess. Affiliations with CSIC-USAL and UAM highlight university roles in translational research.

Postdoctoral and faculty positions in cancer biology are booming. Institutions seek experts in CRISPR modeling, PDX platforms, and inhibitor screening. Platforms like higher-ed-jobs/postdoc list opportunities in Madrid and beyond.

This breakthrough elevates Europe's profile, attracting global talent amid funding boosts from Horizon Europe programs.

Stakeholder Perspectives and Expert Commentary

Mariano Barbacid emphasized: "These results set the course for developing new clinical trials," while cautioning on human translation complexities. Co-author Carmen Guerra noted the therapy's tolerability as key for combinations.

Patient advocates hail it as hopeful, given PDAC's toll—over 69,000 Spanish deaths from 2013-2022. Oncologists view it as validating multi-kinase strategies. Read CNIO's full announcement.

For academics, it spotlights career paths in precision oncology. Craft a winning academic CV to join such teams.

Challenges on the Road to Clinical Trials

Preclinical triumphs don't guarantee human success. PDAC's desmoplastic stroma, immune microenvironment, and patient heterogeneity pose hurdles. Optimizing dosing, pharmacokinetics, and combinations requires phase I trials.

RMC-6236 enters human studies soon; afatinib is approved; SD36 lags. Synergy validation in humans demands investment. European regulators prioritize such rational combos under EMA fast-track.

Ethical considerations include equitable access across EU nations with varying incidences.

Broader Impacts and Future Directions

Beyond PDAC, this informs KRAS-driven lung and colorectal cancers. It accelerates AI-aided drug design and organoids for screening.

In higher education, it fuels curricula in molecular oncology. Universities like Complutense Madrid integrate such cases into PhD programs. Discover Europe university jobs.

Actionable insights: Researchers, monitor PNAS publication; patients, advocate for trials. Browse higher-ed-jobs for oncology roles.

Photo by Jon Tyson on Unsplash

• Track companion diagnostics for KRAS/EGFR/STAT3.
• Support EU funding for combo trials.
• Collaborate via CIBERONC networks.

Optimism for Europe's Oncology Horizon

This CNIO milestone, rooted in Spanish academic excellence, signals progress against PDAC. While years from clinics, it empowers researchers and offers hope. Aspiring academics, seize university-jobs in Europe. Stay engaged via rate-my-professor and higher-ed-career-advice.

Post this study, expect spin-offs, patents, and alliances propelling personalized medicine forward.